Jennison Associates’s Edwards Lifesciences EW Stock Holding History

Jennison Associates’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.6M	Sell	238,403 -12,827,871	-98%	-$1.07B	0.01%	328
2026 Q1	$1.05B	Sell	13,066,274 -714,241	-5%	-$58.9M	0.72%	32
2025 Q4	$1.17B	Sell	13,780,515 -178,259	-1%	-$14.6M	0.71%	34
2025 Q3	$1.09B	Buy	13,958,774 +2,287,783	+20%	+$179M	0.63%	34
2025 Q2	$913M	Buy	11,670,991 +1,584,958	+16%	+$118M	0.54%	36
2025 Q1	$731M	Buy	10,086,033 +2,576,383	+34%	+$184M	0.51%	39
2024 Q4	$556M	Buy	+7,509,650	New	+$526M	0.34%	50
2022 Q3	–	Sell	-7,968	Closed	-$758K	–	623
2022 Q2	$758K	Buy	+7,968	New	+$825K	﹤0.01%	547
2021 Q2	–	Sell	-530,008	Closed	-$44.3M	–	694
2021 Q1	$44.3M	Sell	530,008 -2,084,561	-80%	-$176M	0.03%	234
2020 Q4	$239M	Sell	2,614,569 -819,389	-24%	-$68M	0.17%	62
2020 Q3	$274M	Buy	3,433,958 +649,689	+23%	+$50.7M	0.22%	57
2020 Q2	$192M	Sell	2,784,269 -720,502	-21%	-$51.2M	0.17%	61
2020 Q1	$220M	Sell	3,504,771 -11,169,612	-76%	-$805M	0.27%	55
2019 Q4	$1.14B	Sell	14,674,383 -3,662,379	-20%	-$286M	1.15%	26
2019 Q3	$1.34B	Buy	18,336,762 +219,744	+1%	+$15.4M	1.42%	22
2019 Q2	$1.12B	Buy	18,117,018 +825,546	+5%	+$49.9M	1.11%	28
2019 Q1	$1.1B	Buy	17,291,472 +4,955,073	+40%	+$283M	1.09%	28
2018 Q4	$630M	Buy	12,336,399 +8,003,247	+185%	+$405M	0.7%	41
2018 Q3	$251M	Buy	4,333,152 +1,796,205	+71%	+$87.8M	0.23%	56
2018 Q2	$123M	Buy	2,536,947 +810,144	+47%	+$37.8M	0.12%	121
2018 Q1	$80.3M	Buy	1,726,803 +273,366	+19%	+$11.9M	0.08%	183
2017 Q4	$54.6M	Sell	1,453,437 -1,646,691	-53%	-$60.4M	0.05%	251
2017 Q3	$113M	Buy	3,100,128 +180,954	+6%	+$6.9M	0.12%	137
2017 Q2	$115M	Buy	2,919,174 +14,496	+0.5%	+$529K	0.12%	130
2017 Q1	$91.1M	Buy	2,904,678 +527,082	+22%	+$16.5M	0.1%	177
2016 Q4	$74.3M	Buy	+2,377,596	New	+$77M	0.08%	212
2015 Q3	–	Sell	-170,730	Closed	-$4.05M	–	741
2015 Q2	$4.05M	Buy	+170,730	New	+$3.85M	﹤0.01%	554

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Jennison Associates's EW Position: Q2 2026 in Review

Jennison Associates reduced its Edwards Lifesciences (EW) stake by 98% in Q2 2026, selling an estimated $1.07B and leaving 238,403 shares worth $21.6M. The position accounts for 0.01% of the portfolio, ranked #328.

Jennison Associates first reported a position in EW in Q2 2015 and has held it in 27 quarters since. The position peaked at $1.34B in Q3 2019. 1,330 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Jennison Associates held 238,403 shares of Edwards Lifesciences worth $21.6M as of Q2 2026.
Jennison Associates sold 12,827,871 Edwards Lifesciences shares in Q2 2026, an estimated $1.07B.
Edwards Lifesciences made up 0.01% of Jennison Associates's portfolio in Q2 2026, its #328 holding.
Jennison Associates first reported a position in Edwards Lifesciences in Q2 2015 and has held it in 27 quarters since.
Jennison Associates's Edwards Lifesciences position peaked at $1.34B in Q3 2019.
1,330 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.